Novo Nordisk A/S (NYSE:NVO) Stock Sees Unusually High Call Option Buying

Posted by Brian Himes on Nov 4th, 2026

Novo Nordisk A/S (NYSE:NVO – Get Free Report) saw some unusual options trading activity on Wednesday. Traders acquired 63,116 call options on the company. This represents an increase of 14% compared to the typical daily volume of 55,182 call options.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Novo beat Q3 earnings and revenue estimates, reporting $0.88 per share versus $0.73 expected and $12 billion in revenue versus $11.07 billion expected. Obesity-drug sales rose 22%, supporting the results. Article: NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised
Positive Sentiment: The company raised its full-year 2026 sales and operating-profit outlook. Stronger obesity-treatment demand, including outside the U.S., and Wegovy pill sales that reportedly exceeded expectations helped drive the upgrade. Article: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
Positive Sentiment: CEO Mike Doustdar said patient volumes have grown strongly despite pricing-related pressure, and played down the prospect of dramatic changes to the company’s business environment. These comments may ease investor concerns about pricing and policy risks. Article: Novo CEO Brushes Off Post-Midterm Drug-Pricing Fears
Neutral Sentiment: Novo disclosed that CFO Karsten Munk Knudsen will leave the company. The announcement adds a leadership transition to the news flow, but no further details on its impact were provided. Article: Novo Nordisk’s CFO Karsten Munk Knudsen to leave company
Negative Sentiment: Diabetes weakness and pricing pressures remain risks to growth. Impairment charges also weighed on reported operating profit, although adjusted results were stronger than expected. Article: Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of research analyst reports. UBS Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Barclays reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Cfra downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price target for the company. in a report on Tuesday, September 22nd. Finally, Jefferies Financial Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus target price of $59.44.

Get Our Latest Report on NVO

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently modified their holdings of the business. Scarborough Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at about $26,000. Root Financial Partners LLC acquired a new position in shares of Novo Nordisk A/S during the third quarter valued at about $32,000. Continuum Advisory LLC acquired a new stake in Novo Nordisk A/S in the second quarter valued at approximately $38,000. Latitude Advisors LLC bought a new position in shares of Novo Nordisk A/S in the third quarter valued at $38,000. Finally, Markowski Investments acquired a new position in Novo Nordisk A/S during the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 6.4%

Shares of Novo Nordisk A/S stock traded up $2.58 on Wednesday, hitting $42.77. The stock had a trading volume of 13,690,729 shares, compared to its average volume of 16,399,420. The stock has a 50 day moving average of $40.97 and a 200 day moving average of $44.15. The firm has a market capitalization of $190.96 billion, a P/E ratio of 10.43, a PEG ratio of 1.37 and a beta of 0.70. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.73 by $0.15. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The business had revenue of $12 billion for the quarter, compared to the consensus estimate of $11.07 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

About Novo Nordisk A/S

(Get Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.